Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George R Uhl

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonismGeorge R Uhl
Pharmacogenomics|July 17, 2009
Promise of pharmacogenomics in smoking cessationGeorge R Uhl
Annals of the New York Academy of Sciences|November 11, 2008
Addiction Reviews. PrefaceGeorge R Uhl
Frontiers in Psychiatry|May 4, 2023
Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase DGeorge R Uhl
Annals of the New York Academy of Sciences|October 23, 2014
Preface for Addiction ReviewsGeorge R Uhl
Neuropharmacology|October 7, 2004
Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic processGeorge R Uhl
Annals of the New York Academy of Sciences|November 16, 2004
Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan resultsGeorge R Uhl
Addiction (Abingdon, England)|June 20, 2003
Are over-simplified views of addiction neuroscience providing too simplified ethical considerations?George R Uhl
Psychopharmacology|April 30, 2003
Needed: mouse/human cross validation of reinstatement/relapse models (and drug reward models) to model human substance abuse vulnerability allelic variantsGeorge R Uhl
Annals of the New York Academy of Sciences|March 6, 2010
Introduction to Addiction Reviews 2George R Uhl
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonismGeorge R Uhl
Pharmacogenomics|July 17, 2009
Promise of pharmacogenomics in smoking cessationGeorge R Uhl
Annals of the New York Academy of Sciences|November 11, 2008
Addiction Reviews. PrefaceGeorge R Uhl
Frontiers in Psychiatry|May 4, 2023
Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase DGeorge R Uhl
Annals of the New York Academy of Sciences|October 23, 2014
Preface for Addiction ReviewsGeorge R Uhl
Neuropharmacology|October 7, 2004
Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic processGeorge R Uhl
Annals of the New York Academy of Sciences|November 16, 2004
Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan resultsGeorge R Uhl
Addiction (Abingdon, England)|June 20, 2003
Are over-simplified views of addiction neuroscience providing too simplified ethical considerations?George R Uhl
Psychopharmacology|April 30, 2003
Needed: mouse/human cross validation of reinstatement/relapse models (and drug reward models) to model human substance abuse vulnerability allelic variantsGeorge R Uhl
Annals of the New York Academy of Sciences|March 6, 2010
Introduction to Addiction Reviews 2George R Uhl
Pageof 19